NVSEF
Novartis AG
Novartis AG historical holders
total: 1
US Equity Fund Novartis AG transactions over time
- Total transactions:
- 24
- New positions:
- 1
- Added:
- 7
- Reduced:
- 16
- Held since:
- 2019 Q3
- Held for:
- 27 quarters
- Latest activity:
- 2026 Q1
Independent Franchise Partners has been an institutional investor in Novartis AG (NVSEF) since 2019 Q3. According to 2026 Q1 report, Independent Franchise Partners holds 342,161 shares with a market value of roughly $51.95M representing 3.51% of their equity portfolio. The fund/company first acquired NVSEF in 2019 Q3, initially purchasing 976,113 shares. Since the initial investment, US Equity Fund has made 23 more transactions in this position.
Does Independent Franchise Partners still hold NVSEF?
Yes, Independent Franchise Partners continues to hold Novartis AG (NVSEF). According to their 2026 Q1 report, they maintain a position of 342,161 shares valued at approximately $51.95M, representing 3.51% of their equity portfolio.
When did Independent Franchise Partners first invest in NVSEF?
Independent Franchise Partners first invested in Novartis AG (NVSEF) in 2019 Q3 at the reported quarter-end price of $86.71 per share, acquiring 976,113 shares in their initial purchase.
What is Independent Franchise Partners's average cost basis for NVSEF?
Based on historical transaction data, Independent Franchise Partners's estimated cost basis for Novartis AG (NVSEF) is approximately $88.89 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $88.89
- Weighted AVG sell price:
- $97.83
NVSEF transactions history by US Equity Fund
24 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
3.51%
|
342,161
|
$151.83
|
$51,950,148
|
+2.43% (+8,115)
|
+0.08%
|
|
2025 Q4
|
2.95%
|
334,046
|
$138.37
|
$46,220,732
|
-8.73% (-31,950)
|
-0.27%
|
|
2025 Q3
|
2.81%
|
365,996
|
$125.77
|
$46,031,681
|
-15.55% (-67,398)
|
-0.58%
|
|
2025 Q2
|
3.62%
|
433,394
|
$121.20
|
$52,529,461
|
+0.13% (+575)
|
+0%
|
|
2025 Q1
|
3.43%
|
432,819
|
$110.59
|
$47,865,956
|
+16.75% (+62,091)
|
+0.49%
|
|
2024 Q4
|
3.30%
|
370,728
|
$97.74
|
$36,233,346
|
-38.79% (-234,968)
|
-1.17%
|
|
2024 Q3
|
3.54%
|
605,696
|
$114.79
|
$69,526,043
|
-6.63% (-42,996)
|
-0.26%
|
|
2024 Q2
|
3.69%
|
648,692
|
$107.04
|
$69,435,928
|
-4.30% (-29,119)
|
-0.16%
|
|
2024 Q1
|
3.37%
|
677,811
|
$96.88
|
$65,665,407
|
-22.33% (-194,881)
|
-1.02%
|
|
2023 Q4
|
4.76%
|
872,692
|
$100.91
|
$88,062,981
|
-1.15% (-10,115)
|
-0.06%
|
|
2023 Q2
|
4.76%
|
$100.55
|
+2.93% (+25,120)
|
|||
|
2023 Q1
|
4.65%
|
$91.55
|
-0.20% (-1,747)
|
|||
|
2022 Q4
|
4.97%
|
$90.40
|
-3.04% (-26,973)
|
|||
|
2022 Q2
|
4.73%
|
$84.69
|
-2.26% (-20,542)
|
|||
|
2022 Q1
|
4.26%
|
$87.93
|
-10.66% (-108,161)
|
|||
|
2021 Q4
|
4.30%
|
$88.10
|
+32.75% (+250,455)
|
|||
|
2021 Q3
|
3.15%
|
$82.44
|
-1.90% (-14,814)
|
|||
|
2021 Q2
|
3.52%
|
$91.13
|
+28.31% (+171,973)
|
|||
|
2021 Q1
|
2.70%
|
$85.46
|
-0.20% (-1,208)
|
|||
|
2020 Q4
|
3.12%
|
$94.49
|
-0.61% (-3,732)
|
|||
|
2020 Q3
|
3.23%
|
$86.76
|
-13.79% (-97,978)
|
|||
|
2020 Q2
|
3.90%
|
$86.99
|
+19.86% (+117,704)
|
|||
|
2019 Q4
|
3.55%
|
$94.96
|
-39.28% (-383,403)
|
|||
|
2019 Q3
|
4.18%
|
$86.71
|
new
|
|||
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.